scout

Authors

TargetedOnc Staff Writer
Latest Article

FDA Considers New Warning and Label Recommendations for Breast Implants

According to a statement from the FDA, the agency has issued a draft guidance proposing labeling recommendations for breast implant manufacturers that would help patients understand the benefits and risks of implants. The labeling recommendations would include the addition of a boxed warning.

Terence M. Williams MD, PhD
Latest Article

Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer

To determine the frequency and clinical characteristics of parotid gland metastasis from nasopharyngeal cancer and oropharyngeal cancer and define criteria for elective inclusion of parotidean nodes in the radiotherapy clinical target volume.

Teresa Benson, MA, LP
Latest Article

DNA Testing for Breast Cancer Risk: What the Current Medical Evidence Tells Us

While predictive genetic testing is useful and even crucial for many populations, new medical advances are routinely overhyped in the media and misunderstood by consumers and providers alike.

Terri W. McHugh, DO
Tewari
Thaer Khoury
Thao K . Huynh, PharmD , BCOP
Latest Article

Anti-TIGIT and ICI Combinations Supported by Early-Phase Research

Approaches that pair anti-TIGIT antibodies with other immune checkpoint inhibitors have sparked interest among investigators. Results of early-stage studies evaluating these unique combinations were recently presented at the American Association for Cancer Research Annual Meeting 2021. Later-stage studies are ongoing.

Thao Kim Huynh, PharmD
Latest Article

IDH Mutations Offer Hope as a Prognostic Indicator and Treatable Target in Gliomas

Several presentations at the 2019&nbsp;American Society of Clinical Oncology Annual Meeting highlighted a hopeful new direction in the treatment of gliomas, demonstrating the relevance of <em>IDH1/2</em> mutational status and its feasibility as a target of therapy.

This activity is supported by an educational grant from Eisai, Inc.
Thomas Krivak, MD
Tiffany M. Morgan, MD
Latest Article

Abscopal Effect Induction Among Patients With Metastatic Non-Small Cell Lung Cancer

The prognosis for patients with metastatic non&ndash;small cell lung cancer (NSCLC) is poor.&nbsp;However, with recent trials showing improved overall survival with checkpoint inhibitors compared with standard chemotherapy, disease management is changing.

Tomas G. Lyons, MD
Latest Article

Immune Checkpoint Inhibition in Esophagogastric Cancers

The poor prognosis for patients with esophagogastric cancers (EGC) requires the development of newer more effective therapies to further improve the treatment outcomes for this disease. Immunotherapy is a novel treatment strategy that is dramatically changing the treatment landscape for several types of cancers. Cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody and antagonists of the programmed death (PD)-1/PD-ligand 1 are essential immune checkpoint inhibitors that suppress T-cell activation.

Tony Berberabe
Latest Article

The Targeted Pulse: Tune-In to Discover The Most Recent FDA Approvals and Investigators’ Captivating Findings in Glioblastoma and Brain Mets Therapy

Recent cancer treatment breakthroughs include FDA approvals for zenocutuzumab and durvalumab, and sacituzumab tirumotecan gained breakthrough therapy status. In addition, sonodynamic therapy shows promising results in recurrent glioblastoma, and systemic therapy choices impact brain metastases outcomes, according to new research.

Tony Berberabe, MPH

Tony Berberabe, MPH, is the Editor for Targeted Therapies in Oncology. Berberabe received his Bachelor of Arts in Biology from Rutgers University and his Master of Public Health from the University of Medicine and Dentistry in New Jersey.

Latest Article

Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma

Vorasidenib significantly reduces tumor growth rates in grade 2 glioma patients, improving progression-free survival and time to next intervention.

Tony Hagen
Latest Article

Genetic Testing is Essential in NSCLC Prior to Induction Therapy

Testing for driver mutations is essential before initiating therapy in patients with non&ndash;small cell lung cancer, because there is a risk that the type of upfront treatment chosen could add to the toxicity of, and spur resistance to, targeted therapy options, Suresh S. Ramalingam, MD, said at the 14th Annual New York Lung Cancers Symposium.

Tracey L. Evans, MD
Tracey Regan
Latest Article

Q & A With Kimberly L. Blackwell: The Treatment of HER2 Metastatic Breast Cancer

Since its approval in 1998 to treat metastatic disease, trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive breast cancer.

Usha Malhotra, MD
Latest Article

Ramucirumab: A Novel Antiangiogenic Agent for Gastric Cancer and Gastroesophageal Junction Cancer

Advanced gastric cancer and gastroesophageal junction cancers are highly aggressive cancers with poor prognosis and limited treatment options. The VEGF pathway has been one of the key signaling pathways under investigation for these cancers.

Vadim S. Koshkin, MD
Latest Article

Future Directions of Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer

Cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy has been the standard of care in muscle-invasive bladder cancer for almost 2 decades. However, the rates of NAC utilization remain low and many patients are ineligible to receive cisplatin due to diminished renal function or other factors. Additionally, there are no reliable biomarkers routinely used in clinical practice that identify patients most likely to benefit from NAC, and limited prospective comparisons of the NAC regimens.

Vanessa Caceres
Latest Article

Immunotherapy’s Potential in Neuro-Oncology

A plenary session held November 15 at the Society of Neuro-Oncology’s (SNO) 2014 Annual Meeting in Miami Beach focused on immunotherapy’s promise as well as its challenges as a treatment for patients with brain cancer.

Veena Singh, MD
Latest Article

Clinical Validation and Utility of a Liquid Biopsy in NSCLC

Veena Singh, MD, senior vice president and senior medical director, Biocept, Inc., discusses the clinical validation and utility of a liquid biopsy in non-small cell lung cancer (NSCLC) using circulating tumor cells (CTCs) and ctDNA to analyze EGFR, ALK and ROS status.

Vinay Gupta, MD
Latest Article

Novel Proteasome Inhibitors for Multiple Myeloma

The recent approval of the second-generation proteasome inhibitor carfilzomib by the FDA comes nine years after the initial approval of bortezomib, the first-in-class drug of its type.

Virginia Powers
Latest Article

An Expert's Overview of CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer

Inhibition of CDK4/6 results in improvements in progression-free survival in women with estrogen receptor ER-positive HER2-negative metastatic breast cancer whether it is endocrine sensitive or resistant.

Virginia Powers, PhD
Latest Article

Acalabrutinib Shows High Response, Prolonged Survival in Ibrutinib-Intolerant R/R CLL

Bruton tyrosine kinase inhibitor acalabrutinib demonstrated a high rate of response, prolonged survival, and high tolerability in patients with chronic lymphocytic leukemia who demonstrated intolerance to ibrutinib. Findings were presented at the 15th International Conference on Malignant Lymphoma.

Vivek N. Patel, MD
Latest Article

A Phase II Trial of Cetuximab and Docetaxel With Radiation for Head and Neck Cancer

The use of low-dose radiotherapy may offer transient benefits; nonetheless the potential for palliative care exists.

W. Todd Penberthy
Latest Article

Sub-Centimeter Thyroid Nodule Size May Not Offer Good Prognostic Indicator for Biopsy

The rising overall risk of all sizes of malignant thyroid cancer has made clinicians question whether or not sub-centimeter thyroid nodules should also be biopsied.

W. Todd Penberthy, PhD
Latest Article

PD-L1 Strongly Correlates With Papillary Thyroid Cancer Aggressiveness

Investigators at the Mount Sinai School of Medicine, Toronto, Canada, have been working on a potential correlation for aggressiveness and/or disease-free survival in thyroid cancer patients.

Wade T. Iams, MD
Latest Article

RET Rearrangements in Non-Small Cell Lung Cancer

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non&ndash;small cell lung cancer.&nbsp;These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468.

Walter Alexander
Latest Article

Third-Line Eribulin Effective, Safe in Metastatic Breast Cancer

Among patients with HER2-negative stage IIIb/IV breast cancer who have progressed after a taxane or anthracycline therapy, a multicenter single-arm study of third-line eribulin demonstrated both safety and efficacy.

Walter J. Curran Jr, MD
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us